Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 11 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its recent approval from China's NMPA for Venlafaxine Extended-Release Capsules. The capsules are intended for treating various anxiety and mood disorders. This marks the first approval Zydus has received from the NMPA in China.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases